SAB Biotherapeutics Advances SAFEGUARD Trial with Q2 2026 Progress
Event summary
- Over 60 clinical sites activated in the SAFEGUARD study for SAB-142, with enrollment on track to complete by Q4 2026 and topline data expected in 2H 2027.
- Breakthrough T1D awarded a grant to support the PRISE-hATG study of SAB-142 in patients with Stage 3 type 1 diabetes diagnosed between 100 days to 2 years prior.
- Construction began on a second farm facility to expand production capacity and reduce operational risk for long-term commercial supply of SAB-142.
- SAB Biotherapeutics added to the Russell 3000® and Russell 2000® indexes, increasing visibility among institutional investors.
The big picture
SAB Biotherapeutics is advancing its lead candidate, SAB-142, through key clinical milestones in the treatment of type 1 diabetes. The company's strategic focus on expanding production capacity and securing non-dilutive funding highlights its commitment to addressing significant unmet needs in autoimmune disease treatment. The inclusion in the Russell indexes underscores growing institutional interest in the biopharmaceutical sector.
What we're watching
- Clinical Trial Execution
- Whether SAB Biotherapeutics can maintain the current enrollment pace in the SAFEGUARD study and meet the Q4 2026 completion target.
- Regulatory Pathway
- The potential impact of topline data from the SAFEGUARD study expected in 2H 2027 on the regulatory approval process for SAB-142.
- Operational Scalability
- How the expansion of the Tc-Bovine platform production capacity will affect long-term commercial supply and operational risk management.
Related topics